Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic. If you had come across the ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...

Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.

Support for people living with obesity is “insufficient”, experts have said after a new report revealed that some patients are being asked to wait for up to five years for specialist support. Some ...